PARADIGM-HF trial: will LCZ696 change the current treatment of systolic heart failure?
作者信息
Kaplinsky Edgardo
机构信息
Cardiology Unit, Medicine Department, Hospital Municipal de Badalona, Spain. E-mail:
出版信息
J Geriatr Cardiol. 2015 Sep;12(5):470-3. doi: 10.11909/j.issn.1671-5411.2015.05.010.
Abstract
摘要
相似文献
1
PARADIGM-HF trial: will LCZ696 change the current treatment of systolic heart failure?PARADIGM-HF试验：LCZ696会改变目前收缩性心力衰竭的治疗方法吗？
J Geriatr Cardiol. 2015 Sep;12(5):470-3. doi: 10.11909/j.issn.1671-5411.2015.05.010.
2
Role of Angiotensin Receptor-Neprilysin Inhibition in Heart Failure.血管紧张素受体-中性内肽酶抑制在心力衰竭中的作用
Curr Atheroscler Rep. 2016 Aug;18(8):48. doi: 10.1007/s11883-016-0603-4.
3
Critical Questions about PARADIGM-HF and the Future.关于PARADIGM-HF及未来的关键问题。
Acta Cardiol Sin. 2016 Jul;32(4):387-96. doi: 10.6515/acs20151120a.
4
Combining angiotensin II receptor 1 antagonism and neprilysin inhibition for the treatment of heart failure.联合血管紧张素II受体1拮抗作用与中性肽链内切酶抑制作用治疗心力衰竭。
Expert Rev Clin Pharmacol. 2016 Apr;9(4):513-523. doi: 10.1586/17512433.2016.1153423. Epub 2016 Feb 29.
5
Angiotensin II receptor blocker LCZ696 attenuates cardiac remodeling through the inhibition of the ERK signaling pathway in mice with pregnancy-associated cardiomyopathy.血管紧张素II受体阻滞剂LCZ696通过抑制妊娠相关心肌病小鼠的ERK信号通路来减轻心脏重塑。
Cell Biosci. 2019 Oct 21;9:86. doi: 10.1186/s13578-019-0348-1. eCollection 2019.
6
Was the Enalapril Dose Too Low in the PARADIGM-HF Trial?在PARADIGM-HF试验中，依那普利的剂量是否过低？
Cardiol Rev. 2018 Jul/Aug;26(4):196-200. doi: 10.1097/CRD.0000000000000193.
7
Combination Therapy of Renin Angiotensin System Inhibitors and β-Blockers in Patients with Heart Failure.肾素-血管紧张素系统抑制剂与β受体阻滞剂联合治疗心力衰竭患者。
Adv Exp Med Biol. 2018;1067:17-30. doi: 10.1007/5584_2018_179.
8
Clinical trials update from the European Society of Cardiology-Heart Failure meeting 2015: AUGMENT-HF, TITRATION, STOP-HF, HARMONIZE, LION HEART, MOOD-HF, and renin-angiotensin inhibitors in patients with heart and renal failure.2015 年欧洲心脏病学会心力衰竭会议的临床试验更新：AUGMENT-HF、TITRATION、STOP-HF、HARMONIZE、LION HEART、MOOD-HF 以及心力衰竭伴心肾衰竭患者的肾素-血管紧张素抑制剂。
Eur J Heart Fail. 2015 Sep;17(9):979-83. doi: 10.1002/ejhf.340. Epub 2015 Aug 20.
9
Early improvement of symptoms using LCZ696 in a patient with systolic heart failure and a reduced ejection fraction: a case report.
Perfusion. 2016 Nov;31(8):699-702. doi: 10.1177/0267659116660608. Epub 2016 Jul 18.
10
Clinical benefit of eplerenone in patients with mild symptoms of systolic heart failure already receiving optimal best practice background drug therapy: analysis of the EMPHASIS-HF study.依普利酮在已接受最佳标准药物治疗的收缩性心力衰竭轻症患者中的临床获益： EMPHASIS-HF 研究分析。
Circ Heart Fail. 2013 Jul;6(4):711-8. doi: 10.1161/CIRCHEARTFAILURE.112.000173. Epub 2013 Apr 26.
引用本文的文献
1
Changing the treatment of heart failure with reduced ejection fraction: clinical use of sacubitril-valsartan combination.改变射血分数降低的心力衰竭治疗方案：沙库巴曲缬沙坦联合用药的临床应用
J Geriatr Cardiol. 2016 Nov;13(11):914-923. doi: 10.11909/j.issn.1671-5411.2016.11.006.
2
Spotlight on valsartan-sacubitril fixed-dose combination for heart failure: the evidence to date.心力衰竭的缬沙坦-沙库巴曲固定剂量复方制剂聚焦：迄今的证据
Drug Des Devel Ther. 2016 May 9;10:1627-39. doi: 10.2147/DDDT.S84782. eCollection 2016.
本文引用的文献
1
Angiotensin-neprilysin inhibition versus enalapril in heart failure.血管紧张素-脑啡肽酶抑制剂与依那普利治疗心力衰竭的比较。
N Engl J Med. 2014 Sep 11;371(11):993-1004. doi: 10.1056/NEJMoa1409077. Epub 2014 Aug 30.
2
First-in-class angiotensin receptor neprilysin inhibitor in heart failure.心力衰竭的首创血管紧张素受体脑啡肽酶抑制剂。
Clin Pharmacol Ther. 2013 Oct;94(4):445-8. doi: 10.1038/clpt.2013.146. Epub 2013 Jul 19.
3
Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF).在慢性收缩性心力衰竭患者中，双重血管紧张素受体和脑啡肽酶抑制与血管紧张素转换酶抑制的比较：前瞻性比较 ARNI 与 ACEI 对心力衰竭患者全球死亡率和发病率影响的研究（PARADIGM-HF）的原理和设计。
Eur J Heart Fail. 2013 Sep;15(9):1062-73. doi: 10.1093/eurjhf/hft052. Epub 2013 Apr 5.
4
Epidemiology and risk profile of heart failure.心力衰竭的流行病学和风险特征。
Nat Rev Cardiol. 2011 Jan;8(1):30-41. doi: 10.1038/nrcardio.2010.165. Epub 2010 Nov 9.
5
Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi).LCZ696 的药代动力学和药效学研究，一种新型的双重作用的血管紧张素受体-脑啡肽酶抑制剂（ARNi）。
J Clin Pharmacol. 2010 Apr;50(4):401-14. doi: 10.1177/0091270009343932. Epub 2009 Nov 23.
6
2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation.2009年重点更新内容纳入《美国心脏病学会/美国心脏协会2005年成人心力衰竭诊断与管理指南》：美国心脏病学基金会/美国心脏协会实践指南工作组报告：与国际心肺移植学会合作制定。
Circulation. 2009 Apr 14;119(14):e391-479. doi: 10.1161/CIRCULATIONAHA.109.192065. Epub 2009 Mar 26.
7
Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.缬沙坦、卡托普利或两者联合用于治疗合并心力衰竭、左心室功能不全或两者皆有的心肌梗死。
N Engl J Med. 2003 Nov 13;349(20):1893-906. doi: 10.1056/NEJMoa032292. Epub 2003 Nov 10.
8
Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE).奥美沙坦酯与依那普利治疗慢性心力衰竭患者的比较：奥美沙坦酯与依那普利降低事件发生率随机效用试验（OVERTURE）。
Circulation. 2002 Aug 20;106(8):920-6. doi: 10.1161/01.cir.0000029801.86489.50.
9
A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.血管紧张素受体阻滞剂缬沙坦用于慢性心力衰竭的一项随机试验。
N Engl J Med. 2001 Dec 6;345(23):1667-75. doi: 10.1056/NEJMoa010713.
10
The natriuretic peptides in heart failure: diagnostic and therapeutic potentials.心力衰竭中的利钠肽：诊断和治疗潜力
Proc Assoc Am Physicians. 1999 Sep-Oct;111(5):406-16. doi: 10.1111/paa.1999.111.5.406.
Zotero 插件